AbbVie (ABBV) Tops Q3 EPS by 12c, Lifts FY EPS Guidance

AbbVie (NYSE: ABBV) reported Q3 EPS of $2.14, $0.12 better than the analyst estimate of $2.02. Revenue for the quarter came in at $8.24 billion versus the consensus estimate of $8.22 billion.

GUIDANCE:

AbbVie sees Q4 2018 EPS of $7.90-$7.92, versus the consensus of $7.88.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection
• OneMain (OMF) Reiterated at Market Outperform by Citizens on Updated Estimates